Table 4.
Symptom prevalence across women with endometriosis, according to use or non-use of hormonal therapies, and use or non-use of a levonorgestrel-releasing intra-uterine device
| Symptom | Endo+ Hx+ (n=56) | Endo+ Hx− (n=45) | Endo+ Hx+ LIUCD+ (n=17) | Endo+ Hx+ LIUCD− (n=39) | Significance Endo+ Hx+ vs Endo+ Hx− (P-value)* | Significance Endo+ Hx+ LIUCD+ vs Endo+ Hx+ LIUCD− (P-value)* |
|---|---|---|---|---|---|---|
| Dysmenorrhea (%) | 100 | 100 | 100 | 100 | 1 | 1 |
| Stabbing pain (%) | 69.1 | 68.9 | 82.4 | 63.2 | 0.983 | 0.155 |
| Bowel problems (%) | 48.9 | 50 | 47.1 | 51.3 | 0.912 | 0.771 |
| Food intolerances (%) | 66.7 | 63.6 | 52.9 | 68.4 | 0.752 | 0.270 |
| Bladder problems (%) | 20.0 | 20.0 | 17.6 | 21.1 | 1.000 | 0.770 |
| Headaches (%) | 55.6 | 60.7 | 64.7 | 59 | 0.601 | 0.686 |
| Sexual pain (%) | 35.9 | 40 | 37.5 | 41.2 | 0.693 | 0.804 |
| Vulval pain (%) | 38.6 | 43.3 | 35.3 | 47.2 | 0.635 | 0.413 |
| Fatigue (%) | 68.9 | 83.9 | 88.2 | 82.1 | 0.073 | 0.562 |
| Poor sleep (%) | 55.6 | 60.7 | 70.6 | 56.4 | 0.601 | 0.318 |
| Nausea (%) | 50 | 46.4 | 58.8 | 41 | 0.723 | 0.219 |
| Sweating (%) | 20 | 44.6 | 58.8 | 38.5 | 0.009 | 0.159 |
| Dizziness/faint (%) | 62.2 | 62.5 | 52.9 | 66.7 | 0.977 | 0.329 |
| Anxiety (%) | 57.8 | 55.4 | 52.9 | 56.4 | 0.807 | 0.810 |
| Low mood (%) | 57.8 | 58.9 | 64.7 | 56.4 | 0.907 | 0.562 |
Notes: Endo+ Hx+, women with endometriosis confirmed on hormonal therapy; Endo+ Hx+ LIUCD+, women with endometriosis confirmed using hormonal therapy that included a LIUCD; Endo+ Hx+ LIUCD−, women with endometriosis confirmed using hormonal therapy excluding a LIUCD; Endo+ Hx−, women with endometriosis confirmed on no hormonal therapy;
*
chi-squared tests.
Abbreviation: LIUCD, levonorgestrel-releasing intra-uterine contraceptive device.